Cargando…
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
KRAS is frequently mutated in a variety of cancers including lung cancer. Whereas the mitogen-activated protein kinase (MAPK) is a well-known effector pathway of KRAS, blocking this pathway with MEK inhibitors is relatively ineffective. One major contributor to limited efficacy is attributed to the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584737/ https://www.ncbi.nlm.nih.gov/pubmed/27392325 http://dx.doi.org/10.1080/21541248.2016.1210369 |